Ten years ago, on May 11, 2015, the 7th East-West Small Animal Veterinary Conference was held in Xi’an. Among the various of new products, Jiaxing Zhaoyunfan Biotech exhibited a fluorescence immunoassay analyzer at its booth for the first time. This instrument could read diagnostic test card for infectious diseases and automatically generate test result receipts. Since then, fluorescence immunochromatography technology has officially entered the pet diagnostics industry. Immunofluorescence is one of the few diagnostic technologies in the pet industry that originated in China, developed domestically, and now leads internationally.
It is time for the annual East-West Small Animal Veterinay Conference again. This year’s 17th Conference held in Xiamen coincides with the 10th anniversary of the development of pet fluorescence immunoassay technology.
As a manufacturer specializing in fluorescence immunoassay technology, New-Test Biotech has been deeply rooted in this field since its establishment, committed to seeking more development opportunities for immunofluorescence. In 2018, New-Test Biotech improved the underlying fluorescent materials for fluorescence immunoassay, launching rare-earth nanocrystal materials with excellent photothermal stability and fully industrializing their application in the field of fluorescence immunoassay. In September 2019, the company launched feline 3-in-1 antibody test kit with complimentary insurance in the early stage. In October 2022, New-Test Biotech introduced an iterative product in the fluorescence immunoassay field: multiplex panel and multi-channel immunoassay analyzer. In January 2024, the company released an epoch-making new product – New-Test Renal Function Combo Test Kit, which provides a new basis for determining whether substantial renal damage has occurred in cats with urinary obstruction, and has applied for a national invention patent.
The Shift in Pet Age Demographics Will Reshape the Veterinary Diagnosis and Treatment Industry
Since pets cannot speak, their visits to veterinary hospitals primarily depend on whether pet owners can detect that their pets are ill. As a result, infectious diseases, skin diseases, and surgical injuries currently constitute the main cases. With the number of pets approaching a stable period, the main age structure of pets will shift from primarily young cats and dogs to middle-aged and elderly cats and dogs. Consequently, the primary causes of illness and hospitalization will shift from infectious diseases to internal medical diseases.
Internal medical diseases have a cumulative effect. Unlike humans, who actively seek medical attention for early physical discomfort, pets cannot communicate their symptoms. Typically, by the time pet owners notice signs of internal medical issues, the condition has often progressed to a more severe stage due to the accumulation of symptoms. Therefore, compared to humans, pets have a greater need for annual physical examinations, particularly screening tests for early internal medical markers.
High specificity of early disease markers detection is the core advantage of immunoassays
Immunodiagnostic technologies were initially mainly used for rapid detection of infectious diseases in pets, as they enable convenient and rapid high-sensitivity detection of infectious disease antigen proteins in samples. Products such as enzyme-linked immunosorbent assay (ELISA), colloidal gold, fluorescence immunoassay, and chemiluminescence all belong to immunoassay diagnostic products, with differences lying in the use of different observable markers.
Hormones, drugs and proteins, etc. of most small-molecule compounds in nature or living organisms can be artificially developed into antibodies or antigens for specific recognition. Therefore, the detection items covered by immunoassay methods are the most extensive among existing detection techniques. Currently, infectious disease antigens, organ damage biomarkers, endocrine factors, antibodies, and other pet disease-related items are characteristic and advantageous applications of immunoassay.
New-Test Biotech‘s Fluorescence Immunoassay Multiplex Test Provides a Brand-New Solution for Pet Disease Screening
Since New-Test Biotech launched the NTIMM4 multiplex immunoassay analyzer and supporting canine/feline health marker 5-in-1 test kits in 2022, three years of customer usage, statistical analysis of hundreds of thousands of backend data points, and extensive client feedback have shown that the canine and feline health marker 5-in-1 test kits achieve total detection frequencies of 1.27 early internal medicine cases per kit for dogs and 0.56 early internal medicine cases per kit for cats regarding common early-stage issues in major internal organs (liver, gallbladder, pancreas, kidney, heart). Compared to traditional full physical examination protocols (combinations of blood routine, biochemistry, imaging, etc.), this solution offers advantages such as lower cost (equivalent to the cost of one meal per year), higher efficiency (results available in 10 minutes), and better accuracy (immunological indicators are early-specific markers).
Post time: Jun-05-2025
